OBJECTIVE: The burden of Charcot-Marie-Tooth type 1A (CMT1A), the most common inherited peripheral neuropathy, including impact on patient quality of life (QOL) is not well understood. This study aims to qualitatively describe the range of symptoms associated with CMT1A and impact on QOL. METHODS: We performed qualitative interviews with 16 adult CMT1A patients. Each interview was analyzed using a qualitative framework technique to identify and index symptoms by theme. RESULTS: Sixteen patients provided 656 quotes. One hundred forty-five symptoms of importance were identified representing 20 symptomatic themes. Symptoms associated with difficulty with mobility and ambulation, specific activity impairment, and emotional distress were the most frequently mentioned. CONCLUSIONS: Multiple symptoms contribute to CMT1A disease burden, some previously underrecognized. Improved recognition of underrecognized symptoms will optimize patient care and QOL.
OBJECTIVE: The burden of Charcot-Marie-Tooth type 1A (CMT1A), the most common inherited peripheral neuropathy, including impact on patient quality of life (QOL) is not well understood. This study aims to qualitatively describe the range of symptoms associated with CMT1A and impact on QOL. METHODS: We performed qualitative interviews with 16 adult CMT1A patients. Each interview was analyzed using a qualitative framework technique to identify and index symptoms by theme. RESULTS: Sixteen patients provided 656 quotes. One hundred forty-five symptoms of importance were identified representing 20 symptomatic themes. Symptoms associated with difficulty with mobility and ambulation, specific activity impairment, and emotional distress were the most frequently mentioned. CONCLUSIONS: Multiple symptoms contribute to CMT1A disease burden, some previously underrecognized. Improved recognition of underrecognized symptoms will optimize patient care and QOL.
Authors: P Vinci; M Serrao; A Millul; A Deidda; F De Santis; S Capici; D Martini; F Pierelli; V Santilli Journal: Neurology Date: 2005-09-27 Impact factor: 9.910
Authors: J R Lupski; R M de Oca-Luna; S Slaugenhaupt; L Pentao; V Guzzetta; B J Trask; O Saucedo-Cardenas; D F Barker; J M Killian; C A Garcia; A Chakravarti; P I Patel Journal: Cell Date: 1991-07-26 Impact factor: 41.582
Authors: Chad Heatwole; Rita Bode; Nicholas Johnson; Christine Quinn; William Martens; Michael P McDermott; Nan Rothrock; Charles Thornton; Barbara Vickrey; David Victorson; Richard Moxley Journal: Neurology Date: 2012-07-11 Impact factor: 9.910
Authors: P Raeymaekers; V Timmerman; E Nelis; P De Jonghe; J E Hoogendijk; F Baas; D F Barker; J J Martin; M De Visser; P A Bolhuis Journal: Neuromuscul Disord Date: 1991 Impact factor: 4.296
Authors: Nicholas E Johnson; Chad R Heatwole; Nuran Dilek; Janet Sowden; Callyn A Kirk; Denise Shereff; Michael E Shy; David N Herrmann Journal: Neuromuscul Disord Date: 2014-06-27 Impact factor: 4.296
Authors: Nicholas E Johnson; Chad Heatwole; Peter Creigh; Michael P McDermott; Nuran Dilek; Man Hung; Jerry Bounsanga; Wan Tang; Michael E Shy; David N Herrmann Journal: Ann Neurol Date: 2018-08-29 Impact factor: 10.422
Authors: Robert D Guber; Angela D Kokkinis; Alice B Schindler; Roxanna M Bendixen; Chad R Heatwole; Kenneth H Fischbeck; Christopher Grunseich Journal: Muscle Nerve Date: 2017-09-25 Impact factor: 3.217
Authors: Katy Eichinger; Janet E Sowden; Joshua Burns; Michael P McDermott; Jeffrey Krischer; John Thornton; Davide Pareyson; Steven S Scherer; Michael E Shy; Mary M Reilly; David N Herrmann Journal: Front Neurol Date: 2022-06-27 Impact factor: 4.086